R T Silver

843 total citations
24 papers, 620 citations indexed

About

R T Silver is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, R T Silver has authored 24 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 10 papers in Genetics and 7 papers in Pathology and Forensic Medicine. Recurrent topics in R T Silver's work include Chronic Lymphocytic Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Lymphoma Diagnosis and Treatment (4 papers). R T Silver is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Lymphoma Diagnosis and Treatment (4 papers). R T Silver collaborates with scholars based in United States. R T Silver's co-authors include Z Arlin, Robert W. Carey, Robert Abels, Kay Larholt, Anna Maria Storniolo, David H. Henry, Janet Cuttner, S. E. Salmon, J. W. Kugler and Robert J. Jacobson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

R T Silver

23 papers receiving 591 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R T Silver United States 14 345 217 158 128 116 24 620
P. Carlier Italy 17 534 1.5× 177 0.8× 177 1.1× 103 0.8× 96 0.8× 47 763
Tung‐Liang Lin Taiwan 15 394 1.1× 202 0.9× 194 1.2× 102 0.8× 169 1.5× 33 769
Alain Sadoun France 12 432 1.3× 209 1.0× 249 1.6× 126 1.0× 158 1.4× 28 820
Anand P. Jillella United States 15 485 1.4× 222 1.0× 280 1.8× 101 0.8× 107 0.9× 55 866
Elena Pérez‐Ceballos Spain 13 236 0.7× 180 0.8× 107 0.7× 51 0.4× 190 1.6× 25 578
G Castelli Italy 10 155 0.4× 81 0.4× 116 0.7× 68 0.5× 119 1.0× 24 432
TM Fliedner Germany 8 549 1.6× 202 0.9× 196 1.2× 88 0.7× 38 0.3× 13 648
Tzung‐Chih Tang Taiwan 14 216 0.6× 111 0.5× 146 0.9× 34 0.3× 197 1.7× 33 507
J. Bickers United States 10 504 1.5× 88 0.4× 173 1.1× 206 1.6× 40 0.3× 12 676
Stéphane Chèze France 16 700 2.0× 372 1.7× 157 1.0× 27 0.2× 353 3.0× 46 1.0k

Countries citing papers authored by R T Silver

Since Specialization
Citations

This map shows the geographic impact of R T Silver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R T Silver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R T Silver more than expected).

Fields of papers citing papers by R T Silver

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R T Silver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R T Silver. The network helps show where R T Silver may publish in the future.

Co-authorship network of co-authors of R T Silver

This figure shows the co-authorship network connecting the top 25 collaborators of R T Silver. A scholar is included among the top collaborators of R T Silver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R T Silver. R T Silver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abu‐Zeinah, Ghaith, et al.. (2024). DNMT3A Mutations Do Not Affect Treatment Response or Outcomes for Patients with Polycythemia Vera Treated with Interferon Alpha. Blood. 144(Supplement 1). 3190–3190. 1 indexed citations
2.
Coleman, Morton & R T Silver. (2015). The Chemotherapy of Plasma Cell Myeloma and Related Disorders1. Antibiotics and chemotherapy/Antibiotica et chemotherapia. 18. 112–147.
3.
Goldberg, Roger P., et al.. (2014). An Automatic Female Pelvic Medicine and Reconstructive Surgery Registry and Complications Manager Developed in an Electronic Medical Record. Female Pelvic Medicine & Reconstructive Surgery. 20(6). 302–304. 3 indexed citations
4.
Henry, David H., Beth Brooks, Jonas Kügler, et al.. (2006). Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.. PubMed. 1(4). 252–60. 36 indexed citations
5.
6.
Flume, Patrick A., et al.. (2003). Wegener's granulomatosis in patients with rheumatoid arthritis.. PubMed. 30(9). 2064–9. 27 indexed citations
7.
Silver, R T, et al.. (2003). Nodular scleroderma: case report and literature review.. PubMed. 30(11). 2500–2. 14 indexed citations
8.
Stock, Wendy, Carol A. Westbrook, B. Peterson, et al.. (1997). Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study.. Journal of Clinical Oncology. 15(1). 26–36. 26 indexed citations
9.
Perloff, Michael, Larry Norton, Ann H. Korzun, et al.. (1996). Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.. Journal of Clinical Oncology. 14(5). 1589–1598. 42 indexed citations
10.
Kanost, Michael R., Frederick R. Davey, B. Peterson, et al.. (1995). Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B.. PubMed. 9(7). 1116–20. 28 indexed citations
11.
Silver, R T. (1994). New approaches to the treatment of cancer-related anemia: A panel discussion. Seminars in Oncology. 21(2). 36–41. 1 indexed citations
12.
Case, Delvyn C., Robert W. Carey, David H. Henry, et al.. (1993). Recombinant Human Erythropoietin Therapy for Anemic Cancer Patients on Combination Chemotherapy. JNCI Journal of the National Cancer Institute. 85(10). 801–806. 154 indexed citations
13.
14.
Silver, R T. (1992). Chronic myeloid leukemia. Current Opinion in Oncology. 4(1). 66–72. 4 indexed citations
15.
Puccio, Carmelo, Abraham Mittelman, Stuart M. Lichtman, et al.. (1991). A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.. Journal of Clinical Oncology. 9(9). 1562–1569. 73 indexed citations
16.
Ellison, Rose Ruth, Rosemarie Mick, Janet Cuttner, et al.. (1991). The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B.. Journal of Clinical Oncology. 9(11). 2002–2015. 82 indexed citations
17.
Budman, Daniel R., Ann H. Korzun, Joseph Aisner, et al.. (1990). A Feasibility Study of Intensive CAF as Outpatient Adjuvant Therapy for Stage II Breast Cancer in a Cooperative Group: CALGB 8443. Cancer Investigation. 8(6). 571–575. 7 indexed citations
18.
Verma, Ram S., et al.. (1988). Spatial relationship of chromosomes 9 and 22 at metaphase in patients with chronic myelogenous leukemia (CML). International Journal of Cancer. 41(6). 829–831. 2 indexed citations
19.
Coleman, Morton, et al.. (1987). Advances in chemotherapy for large cell lymphoma.. PubMed. 24(2 Suppl 1). 8–20. 36 indexed citations
20.
Green, Manfred S., Carolyn Horton, Monica B. Spaulding, et al.. (1983). Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: a Cancer and Leukemia Group B study.. Journal of Clinical Oncology. 1(9). 559–565. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P. Carlier Breakdown of academic impact, for papers by Tung‐Liang Lin Breakdown of academic impact, for papers by Alain Sadoun Breakdown of academic impact, for papers by Anand P. Jillella Breakdown of academic impact, for papers by Elena Pérez‐Ceballos Breakdown of academic impact, for papers by G Castelli Breakdown of academic impact, for papers by TM Fliedner Breakdown of academic impact, for papers by Tzung‐Chih Tang Breakdown of academic impact, for papers by J. Bickers Breakdown of academic impact, for papers by Stéphane Chèze
Rankless by CCL
2026